Gallium-68 DOTATATE

Phase 2Radiopharmaceutical

SStanford University

Gallium-68 DOTATATE is one of 35 small molecule programs targeting Cardiac Sarcoidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac SarcoidosisActive, not recruiting

Breast CancerActive, not recruiting

Cardiac SarcoidosisPreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

Adenocard

Astellas

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Gallium-68 DOTATATE

SStanford University

Phase 2

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Acupan

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Cytoreductive Surgery

NCT04609592

Clinical

Trials by Indication[1]

Cardiac Sarcoidosis2 trials

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

Completed·UUniversity of Pennsylvania··NCT03746847·20 enrolled

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Completed·MMarcelo F. Di Carli, MD, FACC·N/A·NCT02546388·17 enrolled

Cytoreductive Surgery1 trial

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Recruiting·SStanford University·Phase 1·NCT04609592·10 enrolled

Breast Cancer1 trial

Study of Dotatate Imaging in Breast Cancer

Unknown status·HHoag Memorial Hospital Presbyterian·Phase 2·NCT05880394·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Gallium-68 DOTATATE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gallium-68 DOTATATE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gallium-68 DOTATATE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: SStanford University

Gallium-68 DOTATATE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Cardiac Sarcoidosis2 trials

Cytoreductive Surgery1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News